Garrison Point Advisors LLC Sells 260 Shares of Amgen Inc. $AMGN

Garrison Point Advisors LLC lowered its position in shares of Amgen Inc. (NASDAQ:AMGN) by 4.2% during the second quarter, HoldingsChannel reports. The fund owned 5,936 shares of the medical research company’s stock after selling 260 shares during the quarter. Garrison Point Advisors LLC’s holdings in Amgen were worth $1,657,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of AMGN. Fairvoy Private Wealth LLC raised its holdings in Amgen by 1.1% in the 2nd quarter. Fairvoy Private Wealth LLC now owns 3,171 shares of the medical research company’s stock valued at $885,000 after buying an additional 35 shares during the last quarter. Nicholson Wealth Management Group LLC grew its holdings in Amgen by 0.6% during the 2nd quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company’s stock worth $1,652,000 after acquiring an additional 35 shares during the last quarter. Crumly & Associates Inc. increased its position in Amgen by 3.2% in the 2nd quarter. Crumly & Associates Inc. now owns 1,146 shares of the medical research company’s stock valued at $320,000 after acquiring an additional 36 shares during the period. Maryland Capital Advisors Inc. increased its position in Amgen by 5.2% in the 2nd quarter. Maryland Capital Advisors Inc. now owns 732 shares of the medical research company’s stock valued at $204,000 after acquiring an additional 36 shares during the period. Finally, Lion Street Advisors LLC raised its stake in shares of Amgen by 1.3% during the second quarter. Lion Street Advisors LLC now owns 2,773 shares of the medical research company’s stock valued at $774,000 after acquiring an additional 36 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,267 shares of the firm’s stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the sale, the senior vice president directly owned 7,209 shares in the company, valued at $2,141,000.91. This trade represents a 14.95% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.76% of the stock is owned by company insiders.

Amgen Price Performance

Shares of AMGN opened at $320.20 on Friday. The firm has a market cap of $172.38 billion, a PE ratio of 26.18, a price-to-earnings-growth ratio of 2.61 and a beta of 0.45. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $335.88. The business’s 50 day moving average price is $289.94 and its two-hundred day moving average price is $288.50. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating the consensus estimate of $5.01 by $0.63. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The company had revenue of $9.56 billion during the quarter, compared to analyst estimates of $8.98 billion. During the same quarter in the previous year, the business posted $5.58 EPS. Amgen’s revenue for the quarter was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 12th. Stockholders of record on Friday, November 21st will be issued a dividend of $2.38 per share. The ex-dividend date is Friday, November 21st. This represents a $9.52 annualized dividend and a dividend yield of 3.0%. Amgen’s dividend payout ratio is currently 73.57%.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on AMGN shares. Wall Street Zen raised shares of Amgen from a “hold” rating to a “buy” rating in a research note on Saturday. Raymond James Financial began coverage on Amgen in a research note on Wednesday, September 3rd. They issued a “market perform” rating on the stock. The Goldman Sachs Group decreased their target price on shares of Amgen from $405.00 to $400.00 and set a “buy” rating for the company in a research report on Wednesday. Weiss Ratings upgraded shares of Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Finally, Bank of America boosted their price target on shares of Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a research report on Friday, September 26th. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $308.83.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.